Pro Medicus Limited (ASX:PME): Medical Imaging Contracts and Financial Performance

Aditi Sarkar

20 October 2026 04:53 PM AEDT

Pro Medicus Limited (ASX:PME): Medical Imaging Contracts and Financial Performance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Pro Medicus (ASX:PME) reported FY26 revenue of A$261.7 million, an increase of 22.9%.
FY26 underlying net profit after tax reached A$144.7 million, up 24.1%.
Ten new contracts carried a stated minimum value of A$407 million during FY26.
Cash and other financial assets totalled A$252.3 million at June 2026; the company reported no debt.

Pro Medicus Limited develops medical imaging software used by hospitals, imaging centres and healthcare groups, with its Visage platform providing image viewing, workflow and archive applications. The company’s August 2026 full-year announcement detailed higher revenue, contract activity and product expansion. On 20 October 2026, Pro Medicus Limited (ASX:PME) was trading at AUD 179.61, up 1.11% for the session, according to the quoted market figures. Its latest operating disclosures provide context for assessing implementation progress, recurring service activity and the mix of reported earnings.

Company Business

Pro Medicus operates across medical imaging software and related healthcare information technology. Its Visage 7 platform supports diagnostic image interpretation and enterprise access to imaging records. The group also offers radiology information systems, picture archiving and communication systems, and other e-health services. The company maintains operations in Australia, Germany and the United States, serving customers in multiple healthcare markets.

The company’s software architecture can be deployed in cloud environments, an important consideration for hospitals replacing legacy imaging systems. Products include imaging viewers, workflow management and archive functionality. For Pro Medicus (ASX:PME), software deployment schedules and the scope of modules adopted by customers are operational measures to monitor alongside reported contract values.

Recent Development

In August 2026, Pro Medicus announced that it signed ten new contracts with a stated minimum value of A$407 million during FY26. It also renewed six contracts, representing A$141 million on five-year terms. These values describe contracted arrangements rather than revenue recognised immediately. The company reported sixteen implementations during the year, making deployment execution relevant to the timing of future recurring revenue.

The FY26 release reported launches covering digital pathology and AI-optimised reporting. It also said implementation work for Trinity was largely complete, positioning the arrangement for a full-year contribution in FY27. Separately, an August 2026 ASX announcement detailed a seven-year A$25 million contract with Valley Health. Pro Medicus (ASX:PME) must still undertake the relevant implementation and ongoing service commitments under individual customer agreements.

During June 2026, the company disclosed a binding heads of agreement with Echo IQ covering a proposed financing and reseller arrangement. The proposed arrangements were subject to further definitive documentation and conditions, so the announcement itself should not be treated as confirmation that all contemplated transactions were completed.

Financial Performance and Sector Context

For the year ended 30 June 2026, Pro Medicus recorded revenue from ordinary activities of A$261.7 million, increasing 22.9%. Underlying EBIT was A$196.1 million, up 24.4%, and the stated EBIT margin was 74.9%. The company reported underlying net profit after tax of A$144.7 million, an increase of 24.1%. On a constant-currency basis, revenue was A$273.5 million, reflecting growth of 28.4%.

Reported net profit after tax reached A$265.3 million, a 130.3% increase. This reported figure included a substantial unrealised fair-value contribution associated with financial investments; it should therefore be distinguished from underlying earnings when assessing software operations. Pro Medicus (ASX:PME) disclosed A$252.3 million in cash and other financial assets at the reporting date and said it remained debt-free.

The board declared a fully franked final dividend of 37 cents per share, taking the FY26 total to 69 cents, up 25.5%. Sector conditions relevant to Pro Medicus include healthcare providers’ technology expenditure, procurement and integration requirements, information security, and demand for imaging workflow efficiency. Currency translation also matters because the company earns revenue outside Australia and reports in Australian dollars.

Risks to Consider

Customer implementations can be delayed by integration complexity, system testing or changing hospital priorities. Procurement cycles and contract concentration can affect the timing of new engagements. Healthcare data privacy and cybersecurity standards create continuing compliance obligations. Competition from other imaging software providers and product development costs may also influence operating performance. For Pro Medicus (ASX:PME), exchange-rate movements and valuation changes on financial investments can widen differences between statutory and underlying results.

What to Watch Next

Monitoring points include completion and activation of contracted installations, revenue recognised from established implementations, further uptake of archive and workflow products, and progress in digital pathology and AI-supported reporting. Future announcements may clarify the status of the Echo IQ arrangement and other commercial partnerships. The company has also identified RSNA 2026 among its forthcoming industry events. The next interim results will provide an updated comparison of revenue growth, margins, cash holdings and reported investment valuation effects.

Key Insights

FY26 combined increased software revenue with new enterprise imaging contracts, product launches and implementation activity. Pro Medicus Limited (ASX:PME) reported underlying earnings growth alongside a higher statutory profit affected by unrealised investment gains. Its debt-free position and liquid financial assets form part of the balance-sheet picture. Future disclosures on contract deployment, operating earnings, currency impacts and product adoption will help distinguish recurring business developments from accounting movements.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.